Ourania Tatsis Sells 1,500 Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) Stock

Key Points

• Vertex EVP Ourania Tatsis sold 1,500 shares on July 2 at an average price of $524.99, generating about $787,485. After the sale, she still held 45,321 shares, and the trade was made under a pre-arranged Rule 10b5-1 plan.
• Vertex stock slipped 1.4% to $522.25, though it remains near its 52-week high of $533.67. Trading volume was well above average, and the company continues to carry a large market cap of about $132.55 billion.
• Vertex recently beat quarterly EPS expectations, reporting $4.47 per share versus the $4.24 estimate, while revenue matched forecasts at $2.99 billion. Analysts remain largely positive, with 21 Buy ratings and a consensus price target of $557.09.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Get Free Report) EVP Ourania Tatsis sold 1,500 shares of the stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $524.99, for a total value of $787,485.00. Following the completion of the sale, the executive vice president owned 45,321 shares in the company, valued at approximately $23,793,071.79. The trade was a 3.20% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vertex Pharmaceuticals Trading Down 1.4%

VRTX traded down $7.34 on Tuesday, hitting $522.25. 2,292,336 shares of the company were exchanged, compared to its average volume of 1,470,929. The firm has a 50-day moving average price of $449.37 and a two-hundred day moving average price of $456.46. Vertex Pharmaceuticals Incorporated has a twelve month low of $362.50 and a twelve month high of $533.67. The company has a market cap of $132.55 billion, a price-to-earnings ratio of 30.98, a price-to-earnings-growth ratio of 2.26 and a beta of 0.29.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings data on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.24 by $0.23. Vertex Pharmaceuticals had a return on equity of 23.86% and a net margin of 35.51%.The business had revenue of $2.99 billion during the quarter, compared to analysts' expectations of $2.99 billion. During the same quarter last year, the business posted $4.06 EPS. The business's quarterly revenue was up 8.3% compared to the same quarter last year. Equities analysts expect that Vertex Pharmaceuticals Incorporated will post 17.02 EPS for the current year.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Large investors have recently modified their holdings of the company. Bangor Savings Bank increased its holdings in shares of Vertex Pharmaceuticals by 0.4% in the 2nd quarter. Bangor Savings Bank now owns 4,470 shares of the pharmaceutical company's stock valued at $2,220,000 after acquiring an additional 20 shares during the period. Earned Wealth Advisors LLC boosted its stake in Vertex Pharmaceuticals by 3.3% during the 4th quarter. Earned Wealth Advisors LLC now owns 650 shares of the pharmaceutical company's stock worth $295,000 after purchasing an additional 21 shares during the period. Confluence Wealth Services Inc. grew its position in Vertex Pharmaceuticals by 4.0% during the 4th quarter. Confluence Wealth Services Inc. now owns 545 shares of the pharmaceutical company's stock worth $247,000 after purchasing an additional 21 shares during the last quarter. Williams Jones Wealth Management LLC. increased its stake in Vertex Pharmaceuticals by 1.9% in the fourth quarter. Williams Jones Wealth Management LLC. now owns 1,155 shares of the pharmaceutical company's stock valued at $524,000 after purchasing an additional 21 shares during the period. Finally, Childress Capital Advisors LLC raised its holdings in shares of Vertex Pharmaceuticals by 3.1% in the fourth quarter. Childress Capital Advisors LLC now owns 730 shares of the pharmaceutical company's stock valued at $331,000 after buying an additional 22 shares during the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.

More Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex’s acquisition of Crinetics gives it access to an approved rare-disease therapy and additional late-stage pipeline assets, strengthening its growth outlook and potentially expanding annual revenue over time. Vertex to Acquire Crinetics Pharmaceuticals
• Positive Sentiment: Broader sentiment around biotech has improved, with Jim Cramer calling the sector “the hottest group in the market” and suggesting merger activity could accelerate, which may support investor enthusiasm for Vertex’s deal-making strategy. Jim Cramer Calls Biotech “The Hottest Group in the Market”
• Neutral Sentiment: Analysts and market commentary are also focusing on how the acquisition may reshape Vertex’s pipeline and valuation, with some investors weighing the strategic benefits against the size of the cash outlay. Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion
• Neutral Sentiment: A separate law-firm investigation into Crinetics’ board could add some legal noise around the transaction, but it is aimed at CRNX rather than Vertex and appears secondary to the acquisition itself. Shareholder Notice: Brodsky & Smith Announces an Investigation of Crinetics Pharmaceuticals, Inc. (CRNX)
• Negative Sentiment: Some traders may view the deal size as a near-term drag on Vertex shares, since large acquisitions can pressure margins, increase integration risk, and require investors to wait for synergies to show up in results. Vertex to buy Crinetics in $10 billion deal

Wall Street Analyst Weigh In

VRTX has been the topic of a number of recent analyst reports. Oppenheimer increased their price objective on shares of Vertex Pharmaceuticals from $540.00 to $600.00 and gave the company an "outperform" rating in a research report on Tuesday, March 10th. Truist Financial began coverage on Vertex Pharmaceuticals in a report on Wednesday, May 27th. They issued a "buy" rating and a $542.00 target price on the stock. HC Wainwright raised their price target on Vertex Pharmaceuticals from $591.00 to $641.00 and gave the company a "buy" rating in a research note on Tuesday, March 10th. Royal Bank Of Canada lifted their price target on Vertex Pharmaceuticals from $543.00 to $570.00 and gave the stock an "outperform" rating in a report on Tuesday. Finally, Jefferies Financial Group started coverage on Vertex Pharmaceuticals in a research report on Tuesday, March 10th. They set a "buy" rating and a $580.00 price objective for the company. Twenty-one equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $557.09.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex's marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.